Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Schwetz, V; Trummer, C; Pandis, M; Grübler, MR; Verheyen, N; Gaksch, M; Zittermann, A; März, W; Aberer, F; Lang, A; Treiber, G; Friedl, C; Obermayer-Pietsch, B; Pieber, TR; Tomaschitz, A; Pilz, S.
Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial.
Nutrients. 2017; 9(5): Doi: 10.3390/nu9050432 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Theiler-Schwetz Verena
Trummer Christian
Co-Autor*innen der Med Uni Graz
Aberer Felix
Grübler Martin
Keppel Martin
Lackner Claudia
März Winfried
Obermayer-Pietsch Barbara
Pandis Marlene
Pieber Thomas
Pilz Stefan
Tomaschitz Andreas
Treiber Gerlies
Verheyen Nicolas Dominik

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011-2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels <75 nmol/L were randomized to 2800 IU of vitamin D daily or placebo for eight weeks. One hundred ninety-seven participants (60.2 ± 11.1 years; 47% women) were included in this analysis. Vitamin D had no significant effect on bALP (mean treatment effect (MTE) 0.013, 95% CI -0.029 to 0.056 µg/L; p = 0.533), CTX (MTE 0.024, 95% CI -0.163 to 0.210 ng/mL, p = 0.802), OC (MTE 0.020, 95% CI -0.062 to 0.103 ng/mL, p = 0.626), or P1NP (MTE -0.021, 95% CI -0.099 to 0.057 ng/mL, p = 0.597). Analyzing patients with 25(OH)D levels <50 nmol/L separately (n = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs.
Find related publications in this database (using NLM MeSH Indexing)
Aged - administration & dosage
Alkaline Phosphatase - genetics, metabolism
Biomarkers - blood
Bone Remodeling - drug effects
Double-Blind Method - administration & dosage
Female - administration & dosage
Gene Expression Regulation - drug effects
Humans - administration & dosage
Male - administration & dosage
Middle Aged - administration & dosage
Osteocalcin - genetics, metabolism
Peptide Fragments - genetics, metabolism
Procollagen - genetics, metabolism
Vitamin D - administration & dosage, analogs & derivatives, blood, pharmacology

Find related publications in this database (Keywords)
vitamin D supplementation
bone turnover markers
procollagen type 1 N-terminal propeptide
bone-specific alkaline phosphatase
© Med Uni Graz Impressum